Literature DB >> 7543140

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

M Saifuddin1, C J Parker, M E Peeples, M K Gorny, S Zolla-Pazner, M Ghassemi, I A Rooney, J P Atkinson, G T Spear.   

Abstract

This study investigates whether cell-derived glycosylphosphatidylinositol-linked complement control proteins CD55 and CD59 can be incorporated into HIV-1 virions and contribute to complement resistance. Virus was prepared by transfection of cell lines with pNL4-3, and primary isolates of HIV-1 were derived from patients' PBMCs. Virus was tested for sensitivity to complement-mediated virolysis in the presence of anti-gp160 antibody. Viral preparations from JY33 cells, which lack CD55 and CD59, were highly sensitive to complement. HIV-1 preparations from H9 and U937 cells, which express low levels of CD55 and CD59, had intermediate to high sensitivity while other cell line-derived viruses and primary isolates of HIV-1 were resistant to complement-mediated virolysis. Although the primary isolates were not lysed, they activated complement as measured by binding to a complement receptor positive cell line. While the primary isolates were resistant to lysis in the presence of HIV-specific antibody, antibody to CD59 induced lysis. Likewise, antibody to CD55 and CD59 induced lysis of cell line-derived virus. Western blot analysis of purified virus showed bands corresponding to CD55 and CD59. Phosphatidylinositol-specific phospholipase C treatment of either cell line-derived or primary isolates of HIV-1 increased sensitivity to complement while incubation of sensitive virus with purified CD55 and CD59 increased resistance to complement. These results show that CD55 and CD59 are incorporated into HIV-1 particles and function to protect virions from complement-mediated destruction, and they are the first report of host cell proteins functioning in protection of HIV-1 from immune effector mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543140      PMCID: PMC2192116          DOI: 10.1084/jem.182.2.501

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  41 in total

1.  Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation.

Authors:  R A June; S Z Schade; M J Bankowski; M Kuhns; A McNamara; T F Lint; A L Landay; G T Spear
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

2.  Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.

Authors:  L A Wilcox; J L Ezzell; N J Bernshaw; C J Parker
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

3.  Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis.

Authors:  D Schols; R Pauwels; J Desmyter; E De Clercq
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

4.  Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study.

Authors:  T Meerloo; M A Sheikh; A C Bloem; A de Ronde; M Schutten; C A van Els; P J Roholl; P Joling; J Goudsmit; H J Schuurman
Journal:  J Gen Virol       Date:  1993-01       Impact factor: 3.891

5.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

6.  Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.

Authors:  M G Wing; J Zajicek; D J Seilly; D A Compston; P J Lachmann
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

7.  Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.

Authors:  C C Delibrias; M D Kazatchkine; E Fischer
Journal:  Scand J Immunol       Date:  1993-08       Impact factor: 3.487

8.  Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV.

Authors:  R J Orentas; J E Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

9.  Complement activation by human monoclonal antibodies to human immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; S Zolla-Pazner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis.

Authors:  I A Rooney; J P Atkinson; E S Krul; G Schonfeld; K Polakoski; J E Saffitz; B P Morgan
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  93 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Expression of MHC class II in T cells is associated with increased HIV-1 expression.

Authors:  M Saifuddin; G T Spear; C Chang; K A Roebuck
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation.

Authors:  Y Takeuchi; S H Liong; P D Bieniasz; U Jäger; C D Porter; T Friedman; M O McClure; R A Weiss
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  CD59 incorporation protects hepatitis C virus against complement-mediated destruction.

Authors:  Tohti Amet; Marwan Ghabril; Naga Chalasani; Daniel Byrd; Ningjie Hu; Ayslinn Grantham; Ziqing Liu; Xuebin Qin; Johnny J He; Qigui Yu
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

5.  Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection.

Authors:  S D Lawn; B D Roberts; G E Griffin; T M Folks; S T Butera
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 6.  Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Authors:  Réjean Cantin; Sylvie Méthot; Michel J Tremblay
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H.

Authors:  Kyung Min Chung; M Kathryn Liszewski; Grant Nybakken; Alan E Davis; R Reid Townsend; Daved H Fremont; John P Atkinson; Michael S Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-28       Impact factor: 11.205

8.  Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.

Authors:  Linda Mark; David G Proctor; David J Blackbourn; Anna M Blom; O Brad Spiller
Journal:  Immunology       Date:  2007-08-30       Impact factor: 7.397

9.  Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins.

Authors:  Kei Sato; Jun Aoki; Naoko Misawa; Eriko Daikoku; Kouichi Sano; Yuetsu Tanaka; Yoshio Koyanagi
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

10.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.